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Abstract
In this article, we examine professional discourse around the development of polygenic risk-
stratified screening (PRSS) for cancer. Analyzing a range of contemporary professional literatures 
from Europe, North America and Australia, we explore how the drive to screen for molecular 
markers of cancer risk makes professionals, screening recipients and publics responsible, in 
different ways, for acquiring, curating and analyzing molecular data. Investigating how these 
responsibilities are invoked in discussions of new data practices, technologies, organizational 
arrangements, engagement, education and protocols for participation, we argue that agendas 
for PRSS for cancer are both expanding and stratifying responsibilities. Data collection is to 
be achieved by intensified responsibilities for including, reassuring and recruiting populations, 
as well as by opening and enriching the datasets on which models and preventative screening 
arrangements are based. Enhanced responsibilities for screening recipients and publics are 
also invoked, not just in relation to personal health but for population health more generally, 
via research participation and consenting to data re-use in the public interest. Professionals, 
screening recipients and publics are also to become responsible for moderating expectations of 
screening according to genomic designations. Together these discourses go beyond individual risk 
management to extend and diversify the responsibilities of practitioners, screening recipients and 
publics as public health genomics develops.
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Introduction
Genomic research and techniques are key to personalized or precision medicine for a 
growing range of conditions, notably cancers (Green and Guyer, 2011; Guttmacher and 
Collins, 2002). In this paper we explore how professional, screening recipient and public 
responsibilities are being reconfigured as public health genomics evolves.
As England’s Chief Medical Officer’s latest Annual Report, Generation Genome 
(Davies, 2017: 1) notes, delivering ‘the genomic dream’ in the National Health Service 
(NHS) requires extensive public engagement and a ‘new social contract between patients 
and the NHS’. Key here is the move away from what one of the report’s authors frames 
as ‘paternalistic’ state-based interventions at a population level, to individual responsi-
bility for prevention based on personalized genomic information (Zimmern, 2017). This 
move would redistribute responsibilities amongst users of population-level services 
according to their polygenic risk, in order to deliver efficiencies and overcome problems 
of overdiagnosis in state-based screening programmes.1 To achieve this, proponents of 
public health genomics point to a range of organizational, social and ethical challenges 
that must be overcome, including public and professional wariness of polygenic risk-
stratified screening (PRSS) and associated interventions in health and lifestyle. This 
invokes a new kind of genomic citizenship (Rose, 2009) with respect to sharing, know-
ing and tending to genomic risks. Professionals, screening recipients and publics also 
gain responsibilities for enabling and supporting PRSS, beyond individuals’ responsibil-
ity for self-management of polygenic risk. These processes of responsibilization recon-
figure the roles and identities of all of these actors as they assume, or are expected to 
assume, responsibilities for delivering and accommodating new screening arrangements 
(Boltanski and Chiapello, 2006; Shamir, 2008).
To understand how these processes of responsibilization operate, we conducted a case 
study of a recent set of professional accounts of research, plans and proposals for PRSS 
for cancer. Drawing on STS and related social scientific literatures, we widen our analy-
sis from the heightening of individual responsibilities for polygenic risk management to 
explore the reconfiguration of professional and public responsibilities that sit alongside 
these processes. We explore the kinds of responsibilities invoked for PRSS research 
infrastructures, data governance, education and participation, and examine how these are 
stratified between and amongst professionals, screening recipients and publics. We argue 
that this diversification and extension of the responsibilities of professionals, screening 
recipients and publics are important aspects of developing markets in public health 
genomics.
Background
STS and other scholars have long been concerned with the implications of genetics and, 
more recently, genomic medicine for citizenship, particularly the extent to which 
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molecular information might be a resource for determinism and discrimination against 
particular groups as responsible for their ‘faulty genes’ (Duster, 2015; Lippman, 1991; 
Shostak and Moinester, 2015). However, there has been little evidence of large-scale 
discrimination against a genetic underclass (Weiner et al., 2017). But STS scholars have 
traced the molecular turn in biomedicine, or ‘the social processes and transformations 
through which phenomena (diseases, identities, pollution, food, racial/ethnic classifica-
tions) are re-defined in terms of their molecular components and described in the lan-
guage of molecular biology’ (Darling et al., 2016: 51). The environment is decentralized 
(Navon, 2011) and de-emphasized (Timmermans and Shostak, 2016) in genomic research 
and related health interventions; the influence of social and environmental factors is 
often measured via their molecular signatures within the body (Darling et al., 2016). 
Genomics has developed from the One Gene One Disease (OGOD) paradigm (Conrad, 
1999) to encompass an appreciation of multiple variants and uncertainties within a para-
digm of malleability (Lappé and Landecker, 2015).
However, the paradigm of malleability can still employ old demographic and epide-
miological categories that ‘naturalize difference’ and turn attention away from the 
social processes through which categories are formed and inequalities perpetuated 
(Prainsack, 2015; see also Duster, 2015). As Ackerman et al. (2016) stress, quantifica-
tion is part of an unfolding moral economy where behavioral and social risks are 
located in the body and responsibilities for their prevention rest with the individual. 
Shostak and Moinester (2015) show how these responsibilities emerge from a range of 
new genomic fields, such as nutritional epigenetics, where the environment is being 
rendered internal to the body and molecular mechanisms become a dominant focus of 
concern and intervention. Meanwhile the broader social-material environment forms a 
kind of ‘fuzzy background’ (Shostak and Moinester, 2015: 223; see also Landecker, 
2011) and the social institutions that negatively affect people’s health and wellbeing 
‘fade from view’ (p. 225). Lappé’s (2016) research on how the maternal body is con-
stituted as an environment in autism research makes a similar point, exploring how, as 
this environment is molecularized, risk is individualized and maternal responsibilities 
for preventing autism are intensified (see also Ackerman et al., 2016; Arribas-Ayllon, 
2016; Darling et al., 2016).
A focus on the molecular reconfigures professional practice across bioscience and 
biomedicine, particularly in relation to data sharing and collaboration. This brings new 
responsibilities for interdisciplinarity and translational agendas (Cambrosio et al., 
2006; Shostak, 2007) as well as engagement with ethical and political questions about 
who should take responsibility for the health risks that these new paradigms identify 
(Darling et al., 2016: 58). Professionals develop a range of technical, institutional and 
engagement strategies as part of the process of molecularizing fields and disciplines 
(Shostak, 2005). As with other innovative health technologies, genomics also involves 
a diversity of social responsibilities for professionals in relation to public engagement 
and responsible innovation, including the need to work with, educate and enable soci-
etal actors to develop new technologies and use services (Davies et al., 2014; Glerup 
and Horst, 2014).
Building on these insights, in this article we explore how the emergent field of public 
health genomics is configuring the responsibilities of professionals, screening recipients 
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and publics. In the next section, we explain our approach to generating a corpus of litera-
ture and the case study of PRSS for cancer.
The case study
Public health genomics, sometimes called public health genetics, developed in the early 
2000’s in North America and Europe (Shostak, 2003). It was defined by the founding 
director of the US Centre for Disease Control’s Office of Public Health Genomics, as ‘the 
application of advances in genetics and molecular biotechnology to improve public health 
and prevent disease’ (Khoury et al., 2000: 5). This field seeks to integrate new molecular 
knowledge into many of the activities of public health – from screening or surveillance, 
through the evaluation and implementation of population interventions to the wider prac-
tices of health education/promotion. This involves professionals from a range of applied 
health fields, notably public health, epidemiology (Bauer, 2013) and bioinformatics 
(Lewis and Bartlett, 2013). A range of professional bodies have been formed (such as The 
Public Health Genomics Foundation in the UK and the Centre for Disease Control’s 
Office of Public Health Genomics in the US) and new journals have come on the scene 
(such as Public Health Genomics, established in 2015). As Bauer (2013) notes, the meth-
odologies of fields such as epidemiology are extending to incorporate concerns such as 
genomic literacy, which she takes as an indicator of change.
The application of genomic knowledge to cancer screening has been one of the main 
planks of these developments, applying rapidly developing molecular understanding of 
cancer etiology to the well-developed infrastructures of cancer screening. Funding agen-
cies such as the European Commission and the Centers for Disease Control and 
Prevention have made significant investment in a range of large-scale interdisciplinary 
and international collaborative programs (e.g., the Collaborative Oncological Gene-
environment Study in Europe). Researchers have advocated a ‘polygenic approach to 
disease prevention’ (e.g. Pharoah, 2003), studying the continuous distribution of risk in 
cancer populations and identifying higher- and lower-risk groups.
To explore how responsibilities are being articulated in this subfield of public health 
genomics, we conducted a case study of professional discourse on PRSS for cancer. We 
explore discussions about cancer in general and about particular cancers, notably breast 
and prostate cancer, as represented in the professional literatures and online commentar-
ies we reviewed. The analysis is also informed by an ongoing multi-sited ethnography of 
contemporary professional, patient and public experiences and approaches to cancer 
genomic diagnostics, treatment and screening. Whilst not all of the multiple actors and 
accounts constitutive of this sub-field are available to our analysis, our dataset neverthe-
less forms an important element of how professionals circulate knowledge and construct 
meaning therein (Arribas-Ayllon, 2016; Myers, 1992).
We searched the Medline database for English-language articles published between 
2012 and 2016, in order to identify articles on PRSS for cancer. This produced 31 articles 
(see Supplemental Appendix).2 We also searched websites and public-facing reports avail-
able via internet searches, to capture the wider discursive processes that make up the sub-
field. This generated a ‘grey’ literature of an additional ten items, including commentary 
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pieces, professional blogs, research reports and magazine articles (see Supplemental 
Appendix). Applying situational analysis (Clarke, 2005), we performed a thematic analysis 
of these texts, which we coded using NVivo, undertaking repeated iterative readings of the 
texts informed by key themes emerging from relevant STS literatures and our wider data 
collection (interviews and observations). We focus on how authors frame the possibilities, 
opportunities and challenges of this emergent field, in relation to understanding genetic, 
genomic and environmental aspects of disease, risk and its management, how existing and 
prospective forms of population screening are presented, and the kinds of actors and 
responsibilities this involves.
The articles, blogs and reports we reviewed are authored by professionals from a 
wide range of applied disciplines and fields, including bioinformatics, oncology, epide-
miology, molecular pathology, genetics, genomic medicine, public health and applied 
health research. Our sample encompasses a range of studies and reviews: Fourteen arti-
cles are quantitative or modelling studies, two are systematic reviews, seven are more 
general review articles (three of which focus on the ethical, legal and social issues of 
risk-stratified screening), six involve social research (both quantitative and qualitative), 
and two are personal view articles (see Supplemental Appendix for an overview of all 
articles per category). Some articles are published in specialist disease-specific or 
organ-specific journals and are relatively focused, for instance reporting on specific 
mutations in a certain form of cancer and reflecting on their implications for screening 
(nine in total). In addition, two articles were published in internal medicine journals, six 
in general cancer journals such as Annals of Oncology, five in genetics journals, two in 
cancer/epidemiology journals, one in Mutation Research, one in Cancer Prevention, 
one in a public health journal, two in Public Health Genomics, and two in medical eth-
ics/internet studies journals. The personal view articles are generally associated with 
one or more of the blogs/reports we included in the sample. Two of the ten blogs identi-
fied were hosted by US agencies: the National Cancer Institute, and the Centers for 
Disease Control and Prevention (both Government funded). One featured on the UK 
Public Health Genomics Foundation website (PHG Foundation – an independent UK 
health policy thinktank) as a supplement to their report on Stratified Screening for 
Cancer (also discussed in this article).
Several authors from the field of public health genomics are prominent in these discus-
sions. Khoury, the founding director of the US Centre for Disease Control’s Office of 
Public Health Genomics, is the first author on one of the academic articles and an author 
on three of the blog reports analysed. Members of a group working with or for the UK 
Public Health Genomics Foundation (Hall, Chowdhury, Dent) contribute to five of the 
articles as well as two of the blogs/reports included in our analyses. Pashayan, who used to 
work for the PHG Foundation, also contributes to eight of the articles and two of the blogs.
Towards polygenic risk-stratified screening
Transformative technoscience
In the articles we reviewed, PRSS for cancer commands great promise. Authors fre-
quently emphasize the benefits of rapid development of more precise genomic information 
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and its potential for improving health through new approaches to screening. In typically 
ebullient language, in a blog post for the Centers for Disease Control and Prevention 
(CDC), Khoury and Richardson (2015) describe it as ‘usher[ing] in a new era of preci-
sion prevention for many diseases in the years to come’. Cancer screening features as a 
key exemplar of how the emergent multidisciplinary agenda for public health genomics 
could be translated into practice (e.g., Pashayan et al., 2013). The rapid growth of molec-
ular epidemiology of cancer is presented as a key driver of change in this field. For 
example, in an article about ‘omics’ and personalizing risk measurements in the online 
magazine Cancerworld (published six times a year by the European School of Oncology), 
Beishon (2017b) notes that in 2007 ‘only a handful of genes’ for breast cancer had been 
identified from Genome Wide Association Studies, but by 2017 more than 150 variants 
were identified for breast cancer and prostate cancer. This presents a narrative of ever 
more detailed and comprehensive sequencing and subsequent actionability. He quotes 
Pharoah, a professor of clinical epidemiology at Cambridge and a leading figure in the 
field, who states that EU funding has supported ‘larger and larger studies needed to find 
things with smaller and smaller effects’. In a ‘personal view’ in the Lancet Oncology, 
Thomas et al. (2015: e303) describe comprehensive models of polygenic risk estimation 
as ‘fundamental to the transformative power of genomic technologies in cancer 
genetics’.3
The novelty and power of these new approaches is emphasized further through a form 
of ‘retrospective accounting’ (Arribas-Ayllon, 2016). Attention is drawn to the limits of 
prior approaches, including the restrictive focus of single gene studies, the emphasis on 
families affected by ‘organ-specific, single-gene breast and bowel cancer syndromes’ 
(Thomas et al., 2015: e303), as well as the dubious clinical validity of some single-high 
-risk-gene tests developed in commercial environments (Dent et al., 2014). Researchers 
also point to the continuing problem of ‘missing heritability’ in current approaches, i.e., 
unidentified rare variants with high or medium penetrance and common variants with 
low penetrance and additive effects. The classification of cancer risk based on these cat-
egories, particularly the ‘binary’ between genes with pathogenic effects and those with-
out, is also queried on the basis that there needs to be a greater recognition of the 
‘continuous range of biological variation’ (Thomas et al., 2015: e304). Here the restricted 
focus of clinical cancer genetics measurements is problematized, particularly the focus 
on rare mutations and only a few cancers (namely breast, ovarian and prostate). As 
Thomas et al. (2015) put it, the established methodologies and classificatory systems of 
clinical cancer genetics are under ‘stress’ (p. e305).
Limitations to established methodologies are also highlighted in articles that explore 
risk stratification for cancer more generally (where polygenic risk is one of a number of 
components being considered), particularly in relation to the problems of relying on fam-
ily history. For example, in a systematic review article on colorectal cancer in Genetics 
and Medicine, an international group of scientists and doctors (Henrikson et al., 2015: 
711) conclude that, although family history remains a ‘clinically meaningful’ way to 
identify those at higher risk and has yet to be superseded by polygenic risk assessment, 
it is nevertheless ‘an imperfect and dynamic measure’, given that comprehensive family 
history is not always available and sometimes ‘hidden’ in families. They also caution that 
‘family history may be under-reported, less well known, or not a primary influence on 
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the excess colorectal cancer burden in African Americans’ (p. 708). Environmental 
measures of risk are also presented as inadequate or unrefined in other articles, for exam-
ple, in those considering how to refine risk measurements based on epigenetic informa-
tion. Pashayan et al. (2016) note:
‘Information collected on environmental exposures via questionnaire or direct measurement is 
susceptible to recall bias and to inadequate capturing of exposures with short half-lives and of 
low biological dose. Epigenetic markers when used in lieu could overcome some of these 
limitations’ (p. 94).
Together, these repertoires position polygenic risk measurement as more comprehen-
sive and better equipped to capture the complexities of family and environmental expo-
sures and to transform the field of public health more generally. Rapid developments of 
technological capacity to capture and analyse more data with more complex methods and 
models in order to produce more accurate estimations of risk are part of a narrative of the 
transformative power of technoscience in general and genomics in particular. This posi-
tions contemporary and historic screening practices as problematic and invokes profes-
sional responsibilities for their transformation via more comprehensive, subtle and 
sophisticated polygenic evidence and models. Researchers from a range of scientific and 
medical backgrounds are being enrolled in the pursuit of a more refined molecular 
regime of cancer risk calculation that would better capture and predict the risks of a 
wider range of cancers, individuals and populations.
Prospective benefits
This vision of transformation also relies on a form of ‘prospective accounting’ (Arribas-
Ayllon, 2016) that emphasizes extending ‘the benefits of personalised risk management 
developed in the single-gene era to the general population’ (Thomas et al., 2015: e306) to 
supersede ‘one-size-fits all approaches’ (Pashayan et al., 2013). For example, in another 
CDC blog Khoury (2013) notes the benefits of moving away from screening applied to 
the ‘average’ person to a program based on subgroups with different levels of risk. In a 
report on their European Commission-funded study of prevention and screening for 
breast, ovary and prostate cancer, the PHG Foundation’s Dent et al. (2014) advocate strati-
fication, because this will provide more effective early treatment for those diagnosed, 
reduce unnecessary surveillance for lower-risk groups and cut healthcare system costs.
Researchers are nevertheless circumspect about the benefits of polygenic risk strati-
fication in existing programmes, anticipating only modest improvements in the accu-
racy of current age-stratified and family-history-stratified screening e.g. for breast 
cancer (Dent et al., 2014). Instead, attention is directed towards the benefits of future 
stratification. For example, in a discussion of the Gail Model (a risk assessment tool 
combining a range of factors to estimate the likelihood of a woman developing invasive 
breast cancer), Beishon (2017b) asserts that adding information on polygenic risk and 
breast density only modestly increases discriminatory power and instead suggests that 
‘the impact could be more substantial in stratifying the population into different risk 
groups’ (Beishon, 2017; see also Pashayan et al., 2016).
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Authors also suggest a range of obstacles that will have to be overcome. These prin-
cipally relate to the need for an evidence base that draws from genetic and other risk 
information, supported by public acceptability and health system readiness (e.g. the ‘spe-
cial article’ in Genetics and Medicine, by Khoury et al., 2013). Here the responsibilities 
of professionals extend to encompass education, evaluation and public relations, build-
ing on their core responsibility for data collection. The gathering of an array of further 
supporting evidence and data is framed as fundamental to the prospects for this kind of 
screening. Researchers in polygenic risk are encouraged to ‘discover’ the significant 
number of additional genetic and genomic factors that remain to be identified (Litchfield 
et al., 2015). Here the population is framed as a resource for further genomic data-collec-
tion via existing screening programs. The measurability of genomic data is one of its key 
advantages, according to these advocates. As Beishon (2017b) notes, it is not that these 
data are, sui generis, ‘superior’, but that they can be measured ‘incredibly accurately’. In 
their Genetics in Medicine article, Khoury et al. (2013) also prioritize the need for empir-
ical data, arguing that this is paramount to the success of PRSS for common diseases and 
making the point that although it has yet to be established that PRSS is better than the 
current model, polygenic data are easy to measure at any point in the lifecourse, as it 
precedes the development of disease.
In these accounts, benefits are largely prospective and depend on professionals deliv-
ering more comprehensive and extensive genomic data and analysis. As epidemiologists 
Fachal and Dunning (2015) explain in their article on Genome Wide Association Studies 
to support PRSS for breast cancer, this in turn requires ‘even larger cohorts of breast 
cancer patients, as well as the development of new statistical methods to comprehen-
sively evaluate combinations of variants conferring low to moderate increases in risk of 
an already complex disease’ (pp. 38–39). Developments therefore hinge on increased 
participation in research by screening recipients, patients and wider populations. A par-
ticular issue arises with respect to ethnicity, as there is a predominance of participants 
with European ancestry in these studies. Limited (sub)populations create problems for 
stratifying individuals. Researchers note that these problems arise because researchers 
sometimes exclude other ethnicities due to ‘limited sample size’ (Joshi et al., 2014: 1025) 
or restrict their systematic reviews to studies from Europe, North America and Australia 
(Mavaddat et al., 2015). Because of such limiations, we see calls for more data to be col-
lected; for example, ‘additional studies will be required to develop and validate genetic 
profiles for other populations, in particular Asian and African populations’ (Mavaddat 
et al., 2015: 7).
In these various accounts of the transformative potential of PRSS and its prospective 
benefits, then, researchers from across the fields of epidemiology, molecular pathology, 
oncology and public health are responsible for collecting and modelling more data, with 
more biological features from more individuals and (sub)populations, about more can-
cers. The generation and measurement of data are key to the ambition of research pro-
jects and international collaborations but also the overall vision for PRSS. Crucially, 
molecular data are particularly valued, because of their amenability to measurement, 
including as proxies for environmental risks. This approach to data is also presented as 
qualitatively different from previous methods rooted in the more traditional focus on 
populations of European descent, family history, close genotype-phenotype associations 
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and rare high penetrance genes in clinical genetics: ‘The genetics of cancer risk will shift 
from a qualitative basis rooted in a binary classification of variation into a more nuanced 
and quantitative form’ (Thomas et al., 2015: e307).
Alongside optimistic discourses of transformation and prospective benefits, we also 
find narratives of incrementalism, with new quantitative analyses and tools of prediction 
added into existing risk measures and screening programmes. Attention is focused on the 
molecular level and on particular diseases where screening might be most plausible (i.e., 
breast cancer and other women’s cancers, colorectal and prostate cancer). Researchers 
also build upon current genetic and age-stratified screening approaches to develop 
strategies for common diseases more generally. The uncertainties and limitations of 
current or previous approaches are to be solved by the collection of yet more data, including 
about populations with non-European ancestry, to develop more refined models. Here we 
find echoes of Timmermans et al.’s (2017) analysis, whereby uncertainties are positioned 
as productive of future improvements in understandings of genetic causality. We also see 
elements of what Reardon (2013) describes with respect to commercial initiatives such 
as 23andme, where inclusion in the dataset is presented as a route to improved health and 
attention is drawn away from the social and environmental risks of disease. In these 
accounts, problematic inaccuracies in environmental and family history information will 
be overcome with more measurable, molecular information gathering and more analysis. 
The acknowledged limitations of these new polygenic approaches in terms of their 
absolute improvement in risk estimations or their ability to resolve problems of overdiag-
nosis are also rendered less significant via appeals to the wider transformational potential 
of stratified screening – ever increasing molecular data collection is both the driver for 
and the product of these initiatives.
Extending responsibilities for PRSS
Developing PRSS extends researchers’ responsibilities for the richness and openness of 
molecular data towards the effective implementation of stratified screening. Dent et al. 
(2013) note this demands ‘substantial organisational effort’ (p. 98), and Beishon (2017a) 
stresses how difficult it will be to ‘turn around major public health programs that have 
considerable bureaucracy and investment in certain IT systems and core beliefs’. Authors 
claim that transforming organizational infrastructures and cultures is key to the delivery 
of PRSS (Pashayan et al., 2013) and that radical integrations of discovery and interven-
tion are required to make this work (Thomas et al., 2015). They invoke partnership and 
organizational entrepreneurship to overcome the bureaucracy, boundaries and core 
beliefs of current state-based programs that limit the acquisition and analysis of data.
Data infrastructures
A range of new data protocols for enacting these responsibilities, particularly with respect 
to data sharing and re-use, are envisaged in the articles we reviewed. Authors set out the 
case for recruiting screening recipients into ongoing research studies, where their data 
may be used for purposes beyond the provision of a screening result. For example, 
Chowdhury et al. (2013), write:
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Any proposed stratified screening program must consider in detail the relevance of the many 
concerns about genetic information, taking into account the technologies that will be used, the 
implications of the data generated, and its subsequent handling. Important issues will include 
the need for explicit consent for undertaking analysis of DNA; whether the data generated can, 
or should, be used for other purposes; the possibility of generating incidental findings and how 
these should be dealt with; whether the information is relevant for family members and, if so, 
whether and how it would be shared; whether the data would be stored and, if so, with what 
safeguards; and who might have access, including the individual, their family members, 
employers, insurance companies, criminal justice agencies, and researchers. All of these issues 
must be resolved in the program’s design and implementation to the satisfaction of the public, 
professionals, and policy makers. (p. 427)
This anticipates an array of responsibilities for ‘health professionals and stakeholders’ 
(p. 430) to develop appropriate protocols for data handling, communication and safe-
guarding, including in relation to access arrangements with market-based actors such as 
insurance companies. Here professionals and interested publics are being enrolled in 
processes of decision-making about appropriate policies: they are asked to take a view 
on and influence governance mechanisms. Professionals and lay representatives are also 
asked to adopt and deliver new kinds of ethical data infrastructures. Dent et al. (2014) 
also suggest that policy makers need to develop detailed plans that attend to the collec-
tion, retention and storage of data:
Since genotypic and phenotypic data are retained for several purposes, more robust and 
comprehensive systems need to be adopted to safeguard data security, and also to provide an 
infrastructure for dealing with issues such as the need for re-contact, incidental or unsolicited 
findings or changes in capacity to consent. (p. 26)
Generating and sustaining these data governance and management infrastructures 
become a part of professionals’ remit and responsibility to ensure the development of 
PRSS.
Extending consent
PRSS agendas also reconfigure the role of screening recipients. Authors (e.g. Chowdhury 
et al., 2013) stress the need for practitioners to preserve autonomy and not overload 
patients with complex information. They raise concerns about how to communicate inci-
dental findings as knowledge advances and datasets become richer and more comprehen-
sive. For example, Hall et al. (2013) advocate for policies that ‘refine how risk prediction 
information is fed back to screening participants, their health providers or potentially 
affected family members’ (p. 288).
One such policy solution, which the articles we reviewed explore, is ‘dynamic con-
sent’ (e.g. Chowdhury, 2013; Dent et al., 2014). This involves participants agreeing to be 
re-approached to extend their original consent in the context of new uses of their data. Its 
advocates argue that dynamic consent offers flexibility and the preservation of autonomy 
(e.g. Dent et al., 2014) and allows for the possibility that the information on which risk 
assessments are based might change as more data are gathered and analyzed (Chowdhury 
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et al., 2013). Within these arrangements, professionals involved with PRSS would be 
expected to acquire ‘adequate understanding’ to use the new kinds of algorithms and risk 
estimation techniques, and to communicate these with confidence (Dent et al., 2013: 20; 
see also Chowdhury et al., 2013). Dynamic consent also extends responsibilities for 
screening recipients, as they are expected to engage with informed choices now and in 
the future as information about risk develops.
Together these discussions, by colleagues from the humanities, social sciences and 
public health, extend screening professionals’ and recipients’ responsibilities for the gen-
eration and sharing of genomic data, and for onward engagement in the analytical pro-
cess and uptake of results. This is presented as a process of modernization of institutions, 
systems and beliefs. Authors invoke collaboration, flexibility and dynamism, contrasting 
these with the boundaries and rigidities of the past.
Organizational responsibilities
We find parallel contrasts in discussions of organizational change. The articles we 
reviewed outlined a range of system-related responsibilities in discussions of the multi-
ple kinds of evaluation required to operationalize PRSS. Evaluation practices are, of 
course, embedded across health care and service arrangements (Mol, 2008; Pollitt et al., 
2010; Power, 1999) and are a primary way in which professional responsibilities are 
exercised. This is reflected in the literature we reviewed; for example, authors suggest 
that a wide range of data and processes should be subject to evaluation in order to gener-
ate robust information about cost and benefits. As Chowdhury et al. (2013) note,
although modelling can provide estimates of benefit and harm, evidence from empirical data is 
required to decide whether the true benefits of screening outweigh the true harms. For evaluation 
of the screening elements of the program, benefits in terms of reduction in morbidity and 
mortality must be weighed against the harms or costs, including complications of clinical 
investigations, anxiety over abnormal results, overdiagnosis, and even treatment of false-
positive results. (p. 426)
Dent et al. (2014) also discuss the importance of quality assurance:
We recommend that providers of risk stratification incorporating a genotypic element should be 
transparent about the evidence base and quality assurance processes that are used, to ensure 
that, regardless of provider, the risk assessments that are generated are safe, robust, and 
evidence-based. (p. 30)
Once again, the collection of data is key to the exercise of accountability, as is co-operation 
amongst a range of professionals involved in gathering and analysing data and delivering 
services. Crucially, professionals are asked to provide evidence and assurance to the health 
‘marketplace’, to ensure that ‘policy-makers and consumers’ can compare what is being 
‘offered’ when making choices about which service to commission or use (Dent et al., 
2014). Here the need to not only collaborate with but also facilitate an emerging market is 
made explicit.
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These various agendas for data infrastructures, consent and organizational change 
map out a range of new and extended responsibilities. For professionals, this involves 
modernization, flexibility and integration between fields and across time. Data is the 
primary asset, not just to produce new findings, but to enable evaluation and quality 
assurance processes that are key to the development of new markets. Screening recipi-
ents play a part in these processes, too, as research subjects who provide data and retain 
responsibilities for deciding on its uses into the future.
Reimagining publics and participation
We now turn to consider how the responsibilities of professionals and wider publics are 
framed in accounts of trust, communication and education. Professionals’ social respon-
sibilities (Glerup and Horst, 2014) include education and cultivation of publics, where 
publics, in turn, become responsible as partners in PRSS development and governance 
processes as part of an ‘integration rationality’ of co-production.
Education and mitigation of (non-)participation
Particularly striking in these accounts is their parsing of publics into selective ‘affected 
publics’ and problematic or ‘partisan publics’ (Braun and Schultz, 2010). A notable set of 
concerns emerges about lower-risk publics, members of which could be offered less or 
no screening as it becomes stratified along genomic lines. Here authors note the strong 
support for established forms of screening. They suggest that this arises, in part, because 
of public overestimations of the risk of cancer and of the benefits of screening. For exam-
ple, in an article on UK women’s attitudes to genetically-stratified mammography 
screening, Meisel et al. (2015) problematize ‘public perceptions of a “right to be 
screened”’ (p. 238). In this framing, the problem of overdiagnosis becomes an issue of 
excessive public demand, rather than a feature of the screening programme in question 
(see also Khoury et al., 2013; Koitsalu et al., 2016; Kukafka et al., 2015). This focuses 
attention on problematic publics, invoking the responsibility of professionals to provide, 
and the responsibility of publics to receive, education and reassurance about PRSS.
As seen in our group of articles, members of this problematic or partisan public cling 
to old notions of population screening and become inappropriately ‘political’. They are 
no longer identified by molecular models as needing frequent screening, but they may 
object to reduced screening as a rationing of health care.
Where there is already an established screening programme, such as that for breast cancer, there 
may be political or public resistance to a reduction of the screening offered to low-risk groups 
because women have been encouraged for many years to see screening as universally beneficial 
and may regard this reduction as service rationing. This may be exacerbated as, inevitably with 
stratified screening, a small group of women assessed as low risk and receiving less intensive 
or no screening will subsequently develop cancer. This group may feel let down by the screening 
programme and would need to be very carefully managed. (Dent et al., 2014: 21)
Authors invoke professional responsibilities for managing these potentially problematic 
groups (of women). The focus is not simply on education as a corrective. Authors 
Kerr et al. 617
suggest other forms of compromise or mitigation that do not diminish existing services, 
for example, via extending existing screening programs (such as breast screening) to 
high-risk groups and not reducing such screening for low-risk groups (even though this 
would be the logical outcome of stratification). This is contrasted with opportunities for 
the introduction of a more stratified approach in new screening programmes (Chowdhury 
et al., 2013). In so doing, authors avoid attenuating the sense of responsibility that moti-
vates participation in screening and cultivate a heightened sense of responsibility 
amongst newly identified, higher-risk, groups.
These authors also engage in some limited discussion about another kind of problem-
atic public that underestimates its ‘affected-ness’ and ignore or actively resist screening, 
notably ethnic minority groups.
Ethnic minority status was associated with negative attitudes towards attending screening more 
frequently with a higher genetic risk, although there was no relationship with attitudes towards 
risk-stratified screening in general, or towards reducing screening frequency for those at lower 
risk. This suggests that the prospect of more frequent mammography screening may be 
problematic for some subgroups. Breast screening attendance has historically been lower for 
women from ethnic minority groups, with notions of privacy and modesty found to be barriers 
to breast screening participation. Furthermore, cancer fatalism (i.e. the belief that cancer is 
inevitable) is higher in some ethnic groups, which has also been suggested as a reason to forego 
breast cancer screening. (Meisel et al., 2015: 240)
This problematic public is perceived as holding inappropriate beliefs about both cancer 
and risk behavior. While unlikely to attend for screening if identified as ‘affected’, mem-
bers of this public are not seen as challenging other elements of stratified screening in 
general, and thus there is a responsibility for professionals to understand this reluctance 
as cultural.
Genomic citizenship
The texts we reviewed also address the question of how to communicate with and edu-
cate potential screening recipients around the subtleties of risk and the value of reconfig-
ured or new genomic risk-stratified screening for cancer. Authors advocate tailored 
communication about particular screening programs. For example, to avoid confusing 
screening recipients, Dent et al. (2013) suggest that the ‘offer of stratified screening … 
needs to convey the message that the value of screening depends on whether participants 
are low or high risk’ (p. 21). This is not just a technical exercise, but involves an overt 
engagement with politics. For example, in an article on a survey of public attitudes to 
PRSS for breast and prostate cancer in Sweden, a group of psychosocial researchers 
note:
Even if screening would be shown to be clinically beneficial, uptake of risk-based screening 
programs would depend on the attitudes in the population. … Public understanding and interest 
in participating are essential to the success of risk-based screening, because the individuals will 
have to understand what is being offered and why in order to consent to it. Moreover, 
acceptability of stratified screening depends on a recognition that this change in screening 
routines is in the public’s interest. (Koitsalu et al., 2016: 46)
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Here, the authors complement distinctions between affected publics with the cultivation 
of an ethos of public interest: a rational, lower-risk public would be content not to be 
screened. They place particular emphasis on the education of these low-risk individuals 
to avoid the perception of rationing:
One group who may require extra resources and attention are ‘low-risk’ individuals who under 
a risk-stratified approach may no longer be deemed eligible for screening, or may have a less 
intensive regimen; some of whom may develop cancer. In order to avoid undermining wider 
trust in health services, effective communication strategies are needed to ensure that those 
designated as low risk understand that the rationale in their case for withholding or reducing 
screening is also to optimize the benefits and reduce screening-related risks. In other words, 
less screening is about risk reduction not rationing health services. (Hall et al., 2013: 289)
These quotes illustrate a general concern amongst professionals from across disciplines 
to establish the trustworthiness and hence public acceptance of stratified screening, espe-
cially for those who may receive less screening as a result of their lower risk status. In 
contrast with previous times, when communication was focused on encouraging all (or 
most) individuals to consider themselves at risk and to be screened, this communication 
strategy includes an explicit focus on lower-risk individuals. Complex messaging around 
personal risk and the costs and benefits of screening attends to consumer rights but off-
sets this against the public interest in order to disavow health care rationing as a driver 
for these changes. Thus responsibilities for developing more stratified messages sit 
alongside, rather than eclipse, responsibilities for maintaining classic public health mes-
sages. There is still a need to convey the importance of continued vigilance, even amongst 
those designated low risk and hence likely to receive less screening:
Individuals at lower risk will need to be informed that they may still develop cancer, as is the 
case with screen-ineligible younger individuals who are considered to be at low risk under the 
current UK system. (Chowdhury et al., 2013: 428)
These accounts stratify publics’ responsibilities based around genomic designations, 
with lower-risk subgroups responsible for revising down their ideas about entitlement to 
screening. Reworked notions of social solidarity sit alongside these changes. For exam-
ple, in their review of social, ethical and legal aspects of cancer risk-stratified screening, 
Hall et al. (2013) highlight recent research on genetic solidarity, which they define as 
‘the collective commitment of individuals to bear costs to help others with a different 
genotype’ (p. 289). They express concerns that this might be undermined by genetic vari-
ant testing, particularly if it is provided privately, irrespective of risk, raising concerns 
about rationing and ‘distributive justice’ whereby certain marginalized groups might 
benefit less from these tests because of a lack of access. Chowdhury et al. (2013) also 
express concerns that stratified screening could be seen as ‘undermining the principles of 
solidarity and fairness’ (p. 429) of universal programs, prompting further disengagement 
by already marginalized groups and worsening inequalities. Hall et al. (2013, 2014) sug-
gest a range of solutions to these problems. For example, in a discussion of childhood 
genotyping as a feature of stratified population screening, they highlight ‘a need for a 
composite normative framework’ combining ‘population-centric and individualistic 
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approaches’, including ‘less emphasis on the protection of autonomy’ (Hall et al., 2014: 
166). They also call for ‘culturally sensitive and appropriate support’ to different groups 
to ensure inclusivity, suggesting the need to develop an evidence base beyond models 
which ‘rely almost exclusively on studies of Caucasian populations’ (Hall et al., 2013: 
289), echoing the concerns about the populations from which data are derived.
In these accounts, a multidisciplinary group of professionals begin to articulate ethical 
frameworks and models of provision for PRSS for cancer. Authors invoke a form of 
genomic citizenship based around distributing resources in the collective, not just the 
individual, interest. Participants are expected to provide genomic data without the prom-
ise of direct personal benefits, even in the form of screening; this frames participants as 
both research subjects and as potential recipients of results. This model of citizenship 
brings with it a need to manage public trust and markets, mitigating the potentially nega-
tive perception of stratified screening as a process of rationing through education about 
risks, research and service development.
Risk-reducing behaviors
A further set of discussions invokes responsibilities of higher-risk individuals to be com-
mitted to preventative action. A lack of such commitment is typically presented as a 
barrier to effective screening to be remedied by better information and support.4 For 
example, the importance of ‘tailoring’ preventative approaches to encourage appropriate 
‘risk reducing behaviours’, including ‘lifestyle changes’ is emphasized in a review article 
on risk prediction and colorectal cancer (Usher-Smith et al., 2015). Pashayan et al. (2016: 
94) also stress the ‘reversibility’ of epigenetic changes as an ‘opportunity for cancer 
prevention strategies’.
However, in other respects, the public’s growing appetite for risk information and 
personalized approaches to risk reduction is framed as excessive. For example, Meisel 
et al. (2013) are concerned that participants have too much faith in risk-avoidance advice 
and are not sufficiently aware of the limited evidence base for some of this (such as that 
coming from commercial organizations like 23andme). To some extent, authors frame 
this faith in risk management as a feature of the search for control in Western society, 
even though that is inconsistent with other beliefs about cancer and fate. Beishon (2017b) 
quotes a bioethicist, Inez de Beaufort, to underline the complexities of navigating risk 
information and the dangers of ‘overload’:
People should also feel free to take some risk in their lives, she said, so how far should health 
services try and intervene? Will there be services to help people after they have been tested? 
People are now bombarded with risk information and navigating yet more could be hard.
These kinds of accounts frame the popularity of preventative action as good for 
recruitment to stratified screening, but this becomes problematic when it is based on 
over-interpretation or over-dependence on too much or too-vague information, with the 
market implicated in this proliferation. Professionals, screening recipients and wider 
publics thereby acquire responsibilities for filtering and navigating a complex array of 
results from state-based services and commercial outlets to realize the benefits of 
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stratified screening. Together they share responsibilities for being educated about risk 
information and processes which are growing ever more complex. This extends respon-
sibilities from the ‘constant work of modulation of the self in relation to desired forms of 
life’ (Rose, 2009: 80), to engaging with and parsing complex genomic information in 
one’s own and the public interest.
Through these accounts, responsibilities for gathering, managing and interpreting 
information about individual risk extend to managing the risks and benefits of screening 
more generally, including the production of responsibilities to and of the state and the 
collective. Within this, publics are constituted as responsible for calibrating their sense 
of risk against a widening array of data. Yet they are also presented as being ill-equipped 
to do so, because of a lack of education, poor communication or a partisan commitment 
to universal screening. Consequently, members of the public are expected to reorient 
themselves to appreciate the benefits to society of some actors being given less screen-
ing, taking on a sense of genomic and health citizenship more broadly. This reframes 
public concerns around inequality as a problem of misperception and deploys appeals to 
science, representativeness or the state to downplay the extent to which these concerns 
will be realized. Expectations about access and demands for choice in relation to screen-
ing also have to be carefully managed. Professionals and publics thereby share responsi-
bility for developing a hybrid commitment to classic public health and consumerism, 
moralizing state and commercial markets with a sense of the public good including state 
commitment to a high quality, value-for-money service (Shamir, 2008).
Conclusion
In this analysis, we have looked at accounts of polygenic risk-stratified screening for 
cancer. As with other areas of genomics, we find a widening range of diseases and popu-
lations being rendered measurable through molecular traces and uncertainties are pro-
ductive of further molecular data collection (Shostak and Moinester, 2015; Timmermans, 
2015). This extends the responsibilities of professionals, screening recipients, and 
higher- and lower-risk populations and the tools and processes through which they are 
managed, such as consent and data-sharing arrangements.
Recipients or potential recipients of screening become responsible for developing an 
appropriate sense of their risk status and therefore eligibility for screening. Lower-risk 
groups acquire responsibity for developing a sense of proportion around their expecta-
tions, whilst higher-risk groups are required to be more vigilant. Incorporating individu-
alization of responsibility for managing risk via dynamic consent processes and 
intensified surveillance for certain at-risk bodies (Lappé, 2016) and improvements in 
molecular data collection and education as solutions to perceived inequities rather than 
structural change (Reardon, 2013; Shostak and Moinester, 2015), PRSS for cancer elabo-
rates and modulates responsibilities beyond the mitigation of personal risk (Rose, 2009). 
Learning, processing and deriving meaning from ever-more complex genomic risk infor-
mation is required for population benefit as well as recipient’s or potential recipient’s 
personal interest. This requires publics to be rational about risk, to be apolitical and 
non-partisan, to refrain from demanding participation without appropriate (genomic) 
cause and to work together with practitioners in these endeavors: processes of 
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responsibilization that sit alongside ‘the continuous work of the self on the self’ (Rose, 
2009: 80) as genomic risk-based screening develops.
For its advocates, PRSS for cancer is not only a matter of accurately identifying 
individual risk but of stratifying publics according to their perceptions (for example 
of entitlements or of discrimination) in order that corrective interventions (education, 
communication) can be developed. Molecular measures and models align with par-
ticular kinds of responsibilities for data acquisition, modelling, sharing and interpre-
tation, articulated through various protocols and exercises in engagement. Here, 
social scientists lead discussion about how to engage recipients and publics and man-
age the market in the public interest. Professional responsibilities are being extended 
alongside those of potential screening recipients and publics, as they work across 
public-private, institutional, national and disciplinary contexts to prioritize data col-
lection and curation. As part of this, professionals must make arrangements for data 
stewardship and collection via screening, with an eye to public sentiment and con-
cerns. They must be sensitive to a range of different public perspectives and appetites 
for/against marketization and to plan services accordingly. Notably, this does not 
extend to key domains of imperceptibility (Murphy, 2006) regarding education and 
public involvement. There is a lack of attention to the inadequacies of educational 
interventions to increase the uptake of screening (e.g. Hollands et al., 2016), or the 
contribution of screening programmes to excessive public trust and anxiety (Armstrong 
and Eborall, 2012; Howson, 1999). Perhaps most strikingly, we found little discussion 
of how to tackle non-participation by ethnic and other minority groups that have had 
negative experiences of data being reused without consent, or of how to manage 
minority groups’ concerns through new forms of collective research governance. 
Although PRSS for cancer brings with it enhanced professional responsibilities for 
engagement with ethics and politics in relation to education, consent and participa-
tion, the repertoire of responsibilities being promoted in these accounts take other 
responsibilities out of the frame.
The vision of the genomic era explored in this case study of PRSS for cancer is not 
one in which individuals would be subject to enforced surveillance or discrimination on 
the basis of their genetic profiles, as critics of geneticization have feared. Nevertheless, 
our analysis suggests that it does intensify responsibilities for the provision, collection 
and analysis of molecular data and the configuration of market-state arrangements 
through which this will be delivered. In so doing, responsibilities are stratified amongst 
potential screening populations in complex and potentially problematic ways. For 
example, individuals may be asked to get less screening if they are identified as at low 
molecular risk, even when their social and economic circumstances are associated with 
high risk. More generally, there is an expectation in much of this literature that publics 
will take on new responsibilities to educate themselves about the complexities of strati-
fied risk and notions of genetic solidarity, without acknowledgement of the kinds of 
work this would generate, especially for the socially disadvantaged. There is also very 
little attention given to the ways in which professionals will incorporate their enhanced 
responsibilities to maximise molecular data collection in order to deliver the transform-
ative power of technoscience into already intensive workloads, particularly in public 
health systems beset with funding crises. Together, these discourses go beyond 
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individual risk management to extend and diversity the responsibilities of professionals, 
screening recipients and publics to co-produce and consume new markets in public 
health genomics.
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Notes
1. Research has shown that breast cancer screening is associated with high rates of overdiagnosis 
in nearly 1/3 of new cases and screening is not significantly reducing breast cancer mortality 
(Bleyer and Welch, 2012).
2. There were some articles we could not include in our sample, such as the CMO report on 
Generation Genome mentioned above or an article by Hood et al. (2015) on actionable risk 
genes for health and wellness. We limited our search to cancer-specific articles and on a spe-
cific timeframe only, so as to be able to work with a manageable yet comprehensive sample 
of articles.
3. A second line of research is being pursued in relation to epigenetic changes, and to the possi-
bility of identifying proxy measures for raised epigenetic risk that can be combined with other 
environmental and genetic risk information to further target screening effectively (Dent et al., 
2014; Pashayan et al., 2016). Here attention is focused on the power of combining range of 
molecular measures for risk estimation which is both more comprehensive and accurate than 
previous approaches
4. There was limited engagement with clinical and social scientific studies exploring the com-
plexities of how individuals respond to and engage with genetic information, including 
research that shows that genetic information on risk may not impact on behaviour (Hollands 
et al., 2016), or research that suggests that biographical histories and ‘innate beliefs’ may 
outweigh information provided by genetic testing (Bancroft et al., 2014).
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